Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kymera Therapeutics (KYMR) EPS (Basic) (2019 - 2025)

Historic EPS (Basic) for Kymera Therapeutics (KYMR) over the last 7 years, with Q3 2025 value amounting to -$0.94.

  • Kymera Therapeutics' EPS (Basic) fell 1463.41% to -$0.94 in Q3 2025 from the same period last year, while for Sep 2025 it was -$3.6, marking a year-over-year decrease of 5384.62%. This contributed to the annual value of -$2.98 for FY2024, which is 1837.4% down from last year.
  • Kymera Therapeutics' EPS (Basic) amounted to -$0.94 in Q3 2025, which was down 1463.41% from -$0.95 recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' EPS (Basic) peaked at -$0.25 during Q4 2023, and registered a low of -$0.95 during Q2 2025.
  • Its 5-year average for EPS (Basic) is -$0.69, with a median of -$0.7 in 2023.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 9716.52% in 2021, then tumbled by 27712.28% in 2024.
  • Over the past 5 years, Kymera Therapeutics' EPS (Basic) (Quarter) stood at -$0.67 in 2021, then rose by 11.94% to -$0.59 in 2022, then soared by 57.63% to -$0.25 in 2023, then crashed by 277.12% to -$0.94 in 2024, then increased by 0.3% to -$0.94 in 2025.
  • Its last three reported values are -$0.94 in Q3 2025, -$0.95 for Q2 2025, and -$0.82 during Q1 2025.